One insider -- Redmile Group Llc, 10% Owner and Director -- today, acquired 857,143 shares of Fate Therapeutics having a market value of approximately...
Fate Therapeutics (FATE) slipped 1% in extended trade after the biopharmaceuticals company late Wednesday said underwriters participating in its recent...
One Fate Therapeutics insider -- Redmile Group Llc, 10% Owner and Director -- today, acquired 857,143 shares having a market value of approximately...
Redmile Group Llc, 10% Owner and Director, reported a purchase of 857,143 shares of Fate Therapeutics (FATE) on Sep 16, 2019, for $15,000,003. Redmile...
| Address | 3535 General Atomics Court San Diego, California 92121 |
| Phone | +1.858.875.1800 |
| Number of Employees | 104 |
| Recent SEC Filing | 09/17/2019 SC 13D/A |
| President, Chief Executive Officer & Director | J. Scott Wolchko |
| Chief Scientific Officer | Daniel D. Shoemaker |
| Vice President-Clinical Development | Yu Waye Chu |
| Senior Vice President-Corporate Development | Jim Beitel |
| Price Open | $17.85 |
| Previous Close | $17.86 |
| 52 Week Range | $11.00 - 22.82 |
| Market Capitalization | $1.2 B |
| Shares Outstanding | 65.4 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/07/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.22 |
| Beta vs. S&P 500 | N/A |
| Revenue | $4.7 M |
| Net Profit Margin | -934.70% |
| Return on Equity | -50.05% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
